CLINICAL AND ECONOMIC EVALUATION OF CHRONIC DISEASE TREATMENT: A DISCREPANCY BETWEEN THE TRADITIONAL PHARMACOECONOMIC AND SOCIO-ECONOMIC ANALYSES
https://doi.org/10.17749/2070-4909.2017.10.2.044-052
Abstract
About the Authors
O. V. Zhukova
Nizhny Novgorod State Medical Academy
Russian Federation
Russian Federation
Ph.D., senior lecturer, the Department of Management and Economics of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy,
ploshchad’ Minina i Pozharskogo, 10/1, Nizhny Novgorod, 603950
S. V. Kononova
Nizhny Novgorod State Medical Academy
Russian Federation
Russian Federation
PhD, professor, Head of the Department of Management and Economics of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy,
ploshchad’ Minina i Pozharskogo, 10/1, Nizhny Novgorod, 603950
References
1. Briskin B. S., Lomidze O. V. Remedium. 2005; 4: 30-35.
2. Economic evaluation of the effectiveness of drug therapy (pharmacoeconomic analysis). Ed. Prof. P. A. Vorobyev [Ekonomicheskaya otsenka effektivnosti lekarstvennoi terapii (farmakoekonomicheskii analiz). Pod red. prof. P. A. Vorob’eva (in Russian)]. Moscow. 2000; 80 s.
3. Renee J. G. Arnold., Boca Raton F. L. Pharmacoeconomics: From Theory to Practice (Drug Discovery). CRC Press. 2009; 263-273.
4. Zaitseva O. V., Murtazaeva O. A. Voprosy sovremennoi pediatrii. 2011; 10: 148-156.
5. Sharavii A. O., Smirnova S. V. Byulleten’ VSNTs SO RAMN. 2012; 3: 222-225.
6. Khelimskaya I. V., Alekseenko S. A. Dnevnik kazanskoi meditsinskoi shkoly. 2013; 1: 40-42.
7. Hartert T. V., Speroff T., Togias A. et al. Risk factors for recurrent asthma hospital visits and death among a population o f indigent older adults with asthma. Ann Allergy Asthma Immunol. 2002; 89: 467-73.
8. Kolbin A. S., Klimko N. N., Andreev B. V. Kachestvennaya klinicheskaya praktika. 2008; 2: 53-61.
9. Global strategy for the treatment and prevention of bronchial asthma (2012 revision). Translation from English. Ed. A. S. Belevsky [Global’naya strategiya lecheniya i profilaktiki bronkhial’noi astmy (peresmotr 2012 g.). Per. s angl. / Pod red. A. S. Belevskogo (in Russian)]. Moscow. 2012; 108 s.
10. Drobik O. S., Biteeva D. V. Meditsinskii sovet. 2014; 16: 12-16.
11. Zaitseva O. V. Meditsinskii sovet. 2013; 1: 34-41.
12. Shaporova N. L., Trofimov V. I., Marchenko V. N. Atmosfera. Pul’monologiya i allergologiya. 2013; 4: 3-6.
13. Bisgaard H., Zielen S., Garcia M. L. et al. Montelukast reduces asthma exacerbations in 2- to 5-year old children with intermittent asthma. Am. J. Respir. Crit. Care Med. 2005; 171 (4): 315-322.
14. Kulichenko T. V. Montelukast v lechenii allergicheskikh boleznei. Pediatricheskaya farmakologiya. 2006; 3 (4): 32-41.
15. Robertson C. F., Henry R. L., Mellis C. et al. Short course montelukast for intermittent asthma in children: the Pre-Empr Study. Presented at the American Thoracic Society International Conference. USA, [A53] Poster C71, May 2004.
Review
For citations:
Zhukova O.V., Kononova S.V. CLINICAL AND ECONOMIC EVALUATION OF CHRONIC DISEASE TREATMENT: A DISCREPANCY BETWEEN THE TRADITIONAL PHARMACOECONOMIC AND SOCIO-ECONOMIC ANALYSES. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2017;10(2):44-52. (In Russ.) https://doi.org/10.17749/2070-4909.2017.10.2.044-052
Views: 806
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Email this article 